Skip to main content

Table 5 Assessment of associations between proteins plasma membrane expression and pathological data in CRC primary tumours

From: Significance of glycolytic metabolism-related protein expression in colorectal cancer, lymph node and hepatic metastasis

 

MCT1

MCT4

CD147

GLUT1

n

Positive (%)

p

n

Positive (%)

p

n

Positive (%)

p

n

Positive (%)

p

Tumor size (cm)

 ≤4.5

286

93.4

0.389

278

54.7

0.265

283

27.9

0.003

267

29.6

0.466

 >4.5

182

91.2

 

175

60.0

 

180

41.1

 

167

26.3

 

Histological Type

 Adenocarcinoma

417

92.8

0.456

402

57.0

0.862

411

33.6

0.787

386

28.2

0.389

 A. Mucinous

51

90.2

 

49

57.1

 

52

28.8

 

46

26.1

 

 A. Invasive

24

95.8

 

24

54.2

 

23

26.1

 

23

39.1

 

 Signet ring and mucinous

4

75.0

 

3

33.3

 

4

25.0

 

4

0.0

 

Differentiation

 Well-differentiated

219

93.2

0.271

213

56.8

0.070

217

34.6

0.875

202

21.3

0.009

 Moderately-differentiated

209

93.3

 

204

55.4

 

206

32.5

 

197

35.0

 

 Poorly-differentiated

49

85.7

 

43

69.8

 

48

29.2

 

43

39.5

 

 Undifferentiated

4

100.0

 

3

0.0

 

4

25.0

 

3

33.3

 

Tumour Penetration

 Tis

5

100.0

0.946

6

16.7

0.277

4

25.0

0.034

5

0.0

0.436

 T1

30

90.0

 

28

50.0

 

30

13.3

 

27

29.6

 

 T2

59

93.2

 

58

56.9

 

59

30.5

 

55

21.8

 

 T3

376

92.6

 

359

57.7

 

371

33.2

 

350

29.4

 

 T4

24

91.7

 

25

64.0

 

24

54.2

 

20

35.0

 

Spread to lymph nodes

 Absent

280

92.5

0.888

272

54.0

0.269

277

32.5

0.876

263

25.5

0.058

 Present

204

92.2

 

196

59.2

 

202

33.2

 

187

33.7

 

Vessel invasion

 Absent

159

94.3

0.255

159

58.5

0.541

156

33.3

0.817

150

25.3

0.194

 Present

314

91.4

 

299

55.5

 

313

32.3

 

291

31.3

 

TNM

 Stage I

77

92.1

0.566

77

52.0

0.464

77

22.1

0.147

74

23.3

0.206

 Stage II

183

92.9

 

179

57.0

 

181

36.5

 

173

26.0

 

 Stage III

155

94.2

 

151

57.6

 

154

34.4

 

142

30.3

 

 Stage IV

75

88.0

 

67

59.7

 

73

31.5

 

66

39.4

 

BRAF mutations

 Negative

87

94.3

1.000

56

65.9

0.608

33

38.4

0.641

16

19.8

0.196

 Positive (V600E)

4

100

 

2

50.0

 

2

50.0

 

2

50.0

 

KRAS mutations (codon12/13 and 61)

 Negative

78

96.3

0.437

51

64.6

0.217

27

34.2

0.668

17

21.8

0.411

 Positive

41

93.2

 

31

75.6

 

16

38.1

 

6

15.4

 

Microsatellite Instability

 Negative

102

95.3

0.986

66

65.3

0.335

38

36.5

0.321

20

20.2

0.984

 Positive (MSI-L + MSI-H)

20

95.2

 

16

76.2

 

5

25.0

 

4

20.0

Â